Novo Nordisk (NVO) Receives FDA Approval for Wegovy

Novo Nordisk (NYSE:NVO) is one of the Most Profitable Large Cap Stocks to Buy According to Analysts. On August 15, Novo Nordisk (NYSE:NVO) announced that the FDA had approved the use of its new drug Wegovy to treat adults with noncirrhotic metabolic dysfunction-associated steatohepatitis. The drug also moderates advanced liver fibrosis.

The approval follows positive results from the ESSENCE trial, where the drug depicted better results compared to the placebo. At week 72, 36.8% of patients taking Wegovy improved their liver fibrosis without worsening steatohepatitis. Whereas the placebo only improved results in 22.4% of the patients. With the approval, Wegovy is now the first and only GLP-1 drug approved for noncirrhotic metabolic dysfunction-associated steatohepatitis.

Novo Nordisk (NVO) Receives FDA Approval for Wegovy

An elderly couple receiving insulin from a pharmacist, representing healthcare company’s successful pharmaceutical products.

Novo Nordisk (NYSE:NVO) is a global healthcare company specializing in diabetes and obesity care.

While we acknowledge the potential of NVO to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NVO and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.